Sunshine Biopharma, Inc. (NASDAQ:SBFMW – Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 5,818 shares, a growth of 652.7% from the June 30th total of 773 shares. Based on an average trading volume of 5,883 shares, the days-to-cover ratio is presently 1.0 days.
Sunshine Biopharma Price Performance
NASDAQ SBFMW remained flat at $0.06 during trading hours on Friday. The company had a trading volume of 4,090 shares, compared to its average volume of 16,281. The business’s 50 day simple moving average is $0.06 and its two-hundred day simple moving average is $0.11. Sunshine Biopharma has a 1-year low of $0.02 and a 1-year high of $0.65.
About Sunshine Biopharma
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
Further Reading
- Five stocks we like better than Sunshine Biopharma
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
